Designed and created by Guideline Central in participation with the Society of Gynecologic Oncology
Hormone therapy (HT) in Women with Gynecologic Cancers and in Women at High Risk for Developing a Gynecologic Cancer
Publication Date: May 1, 2020
Last Updated: March 3, 2023
This patient summary means to discuss key recommendations from the Society of Gynecologic Oncology (SGO) for hormone therapy (HT) in women with gynecologic cancers.
- Natural menopause occurs gradually as female hormone production declines. Most treatments for cancers in female organs cause a sudden menopause with more severe symptoms.
- Symptoms include hot flashes, night sweats, flushing, sexual and urinary dysfunction, premature bone loss and increased risk of heart and circulation problems.
- This patient summary identifies patients that can be safely treated for menopause without increasing their cancer risk.
- Cancers are usually typed by location and by their appearance under a microscope. Some require genetic studies.
Recommendations for hormone therapy in gynecologic cancer survivors and women at high risk for developing gynecologic cancer
|Patient Status||Type of Cancer||Hormone Therapy|
|Survivors of cancer||Endometrial cancer|
|Early-stage endometrial cancer||Acceptable|
|Advanced stage endometrial cancer||Not recommended|
|Uterine sarcoma||Not recommended|
|High grade serous ovarian cancer||Acceptable|
|Low grade serous and endometrioid ovarian cancer||Not recommended|
|Women at high risk||Breast cancer and Lynch syndrome|
|BRCA mutation with no personal history of breast cancer||Acceptable|
|BRCA mutation with personal history of breast cancer||Not recommended|
|* Lynch syndrome is a genetic condition that increases the risk of many cancers, most commonly in the colon.|
- The growth of most female cancers is increased by female hormones (estrogen and progesterone) that also prevent symptoms of menopause.
- Treatment of these cancers often involves medicines or radiation that inactivates the female hormones or surgery to remove the ovaries that produce the hormones.
- HT: Hormone Therapy
- SGO: Society Of Gynecologic Oncology
Sinno AK, Pinkerton J, Febbraro T, Jones N, Khanna N, Temkin S, Iglesias D, Pothuri B. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society. Gynecol Oncol. 2020 May;157(2):303-306. doi: 10.1016/j.ygyno.2020.01.035. Epub 2020 Feb 15. PMID: 32067815.
The information in this patient summary should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.